Famotidine and Antacids for Treatment of Dyspepsia
Comparing Intravenous Famotidine and Oral Antacids in the Treatment of Dyspepsia in the Emergency Department
Stony Brook University
80 participants
Nov 9, 2023
INTERVENTIONAL
Conditions
Summary
The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
Eligibility
Inclusion Criteria3
- Subject Age ≥ 18 years of age
- Patient diagnosed with dyspepsia
- Present at the ED with upper abdominal pain score of at least 3
Exclusion Criteria8
- Hypersensitivity to an ingredient in Maalox/ Mylanta or Famotidine
- Moderate to Severe Renal Insufficiency (precaution)
- Kidney Failure
- Pregnant or Nursing
- Verbal pain score less than 3
- Inability to tolerate oral medications
- Bowel Obstruction
- Proton pump inhibitor within 2 hours of study treatment
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients in this group will receive 20mg IV Famotidine.
Patients in this group will receive 30 ml Maalox/ Mylanta.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06241183